^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
SL-172154
i
Other names: SL-172154, SIRPα-Fc-CD40L
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Shattuck
Drug class:
CD47 inhibitor, CD40 agonist
Related drugs:
1m
03-OHD-104: Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML (clinicaltrials.gov)
P1, N=160, Recruiting, Shattuck Labs, Inc. | N=107 --> 160 | Trial completion date: Oct 2024 --> Dec 2025 | Trial primary completion date: Feb 2024 --> Apr 2025
Enrollment change • Trial completion date • Trial primary completion date • Combination therapy
|
TP53 (Tumor protein P53)
|
TP53 mutation
|
Venclexta (venetoclax) • azacitidine • SL-172154
4ms
03-OHD-104: Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML (clinicaltrials.gov)
P1, N=107, Recruiting, Shattuck Labs, Inc.
Trial completion date • Trial primary completion date • Combination therapy
|
TP53 (Tumor protein P53)
|
TP53 mutation
|
Venclexta (venetoclax) • azacitidine • SL-172154
5ms
Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers (clinicaltrials.gov)
P1, N=102, Enrolling by invitation, Shattuck Labs, Inc. | Recruiting --> Enrolling by invitation | Phase classification: P1b --> P1
Enrollment status • Phase classification
|
FOLR1 ( Folate receptor alpha )
|
pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx) • SL-172154
6ms
Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML (clinicaltrials.gov)
P1, N=107, Recruiting, Shattuck Labs, Inc. | Phase classification: P1a/1b --> P1
Phase classification • Combination therapy
|
TP53 (Tumor protein P53)
|
TP53 mutation
|
Venclexta (venetoclax) • azacitidine • SL-172154
6ms
Safety, Pharmacodynamic, and Anti-Tumor Activity of SL-172154 As Monotherapy and in Combination with Azacitidine (AZA) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) Patients (pts) (ASH 2023)
The median number of prior lines of AML therapy was 2 [range 1-4]; 25 (93%) had received venetoclax (VEN) and 23 (85%) had received a hypomethylating agent (HMA). SL-172154 was well tolerated up to 3 mg/kg as monotherapy and in combination with AZA. Preliminary efficacy signals were detected in UnTx TP53m-MDS and R/R AML. A response to SL-172154 monotherapy, dose-dependent increases in serum cytokines and accumulation of mature myeloid cells in BM suggest a potential role for CD40 stimulation.
Clinical • PK/PD data • Combination therapy • IO biomarker
|
TP53 (Tumor protein P53) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • CD36 (thrombospondin receptor) • IL10 (Interleukin 10) • ITGAM (Integrin, alpha M) • CD40LG (CD40 ligand) • SIRPA (Signal Regulatory Protein Alpha)
|
TP53 mutation • CXCL8 elevation
|
Venclexta (venetoclax) • azacitidine • SL-172154
12ms
Phase 1 Study of SL-172154 (SIRPα-Fc-CD40L) in Subjects With Ovarian Cancer (clinicaltrials.gov)
P1, N=34, Completed, Shattuck Labs, Inc. | Active, not recruiting --> Completed | Trial completion date: Jul 2023 --> Feb 2023
Trial completion • Trial completion date
|
HRD (Homologous Recombination Deficiency)
|
HRD
|
SL-172154
1year
Phase 1 dose escalation study of SL-172154 (SIRPα-Fc-CD40L) in platinum-resistant ovarian cancer. (ASCO 2023)
SL-172154 is well tolerated in heavily pretreated PROC pts. IRRs were readily manageable. Maximal CD47 and CD40 target engagement and CD40-dependent PD effects were observed with ≥3mg/kg SL-172154.
P1 data
|
CD8 (cluster of differentiation 8) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • CCL20 (C-C Motif Chemokine Ligand 20) • IL10 (Interleukin 10) • CCL2 (Chemokine (C-C motif) ligand 2) • CCL22 (C-C Motif Chemokine Ligand 22) • CD40LG (CD40 ligand) • SIRPA (Signal Regulatory Protein Alpha)
|
SL-172154
over1year
Phase 1 Study of SL-172154 (SIRPα-Fc-CD40L) in Subjects With Ovarian Cancer (clinicaltrials.gov)
P1, N=34, Active, not recruiting, Shattuck Labs, Inc. | Recruiting --> Active, not recruiting | Trial completion date: Jul 2022 --> Jul 2023 | Trial primary completion date: Jul 2022 --> Mar 2023
Enrollment closed • Trial completion date • Trial primary completion date
|
HRD (Homologous Recombination Deficiency)
|
HRD
|
SL-172154
over1year
Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers (clinicaltrials.gov)
P1b, N=102, Recruiting, Shattuck Labs, Inc. | Not yet recruiting --> Recruiting
Enrollment open
|
FOLR1 ( Folate receptor alpha )
|
pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx) • SL-172154
almost2years
Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers (clinicaltrials.gov)
P1b, N=102, Not yet recruiting, Shattuck Labs, Inc.
New P1 trial
|
FOLR1 ( Folate receptor alpha )
|
pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx) • SL-172154
over2years
Phase 1 dose escalation study of the agonist redirected checkpoint, SL-172154 (SIRPα-Fc-CD40L) in subjects with platinum-resistant ovarian cancer (SITC 2021)
Dose escalation is ongoing. Trial Registration NCT04406623
Clinical • P1 data
|
CD8 (cluster of differentiation 8) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CD40LG (CD40 ligand) • SIRPA (Signal Regulatory Protein Alpha)
|
SL-172154
almost4years
Phase 1 Study of SL-172154 (SIRPα-Fc-CD40L) in Subjects With Ovarian Cancer (clinicaltrials.gov)
P1, N=33, Recruiting, Shattuck Labs, Inc. | Not yet recruiting --> Recruiting
Clinical • Enrollment open
|
HRD (Homologous Recombination Deficiency)
|
HRD
|
SL-172154
almost4years
Phase 1 Study of SL-172154 (SIRPα-Fc-CD40L) in Subjects With Ovarian Cancer (clinicaltrials.gov)
P1, N=33, Not yet recruiting, Shattuck Labs, Inc.
Clinical • New P1 trial
|
HRD (Homologous Recombination Deficiency)
|
HRD
|
SL-172154
Share via
